Role of lymphangiogenesis in lung cancer

Folia Histochemica et Cytobiologica

Volumn 47, Issue 3, 2009, Pages 333-342

  Weryńska, Bozena ^a   Dziȩgiel, Piotr ^a,b   Jankowska, Renata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Lung cancer; Lymphangiogenesis; Markers of lymphatic vessels; Vascular endothelial growth factors

Indexed keywords

ANGIOPOIETIN 1; BEVACIZUMAB; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR 2; MARKER; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MICROVASCULATURE; REVIEW; SENTINEL LYMPH NODE; TUMOR CELL; TUMOR GROWTH;

ANIMALIA;

EID: 77149133094     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0090-3     Document Type: Review

References (98)

1. Kawai H, Minamiya Y, Ito M. et al. VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer. 2008;59:41-47.
2. Ginsberg MS. Epidemiology of lung cancer. Semin. Roentgenol. 2005;40:83-89.
3. Szczuka I, Roszkowski-Śliż K. Lung cancer in Poland in 1970-2004. Pneumonol Alergol Pol. 2008;76:19-28.
4. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. Cancer J Clin. 2001;51:15-36.
5. Rennie J, Rusting R. Making headway against cancer. Sci Am. 1996;275:56-59.
6. Folkman J, Klagsburn M. Angiogenic factors. Science. 1987; 235:442-447.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. NEJM. 1991;324,1-8.
8. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 2002;16,922-934.
9. Ryan TJ. Structure and function of lymphatics. J Invest Dermatol. 1989;93:18S-24S.
10. Clarijs R, Ruiter DJ, de Waal R.M. Lymphangiogenesis in malignant tumours: does it occur? J Pathol. 2001;193:43-146.
11. Jussila L, Alitalo K. Vascular Growth Factors and Lymphangiogenesis. Physiol Rev. 2002;82:673-700.
12. Leak LV, Burke JF. Fine structure of the lymphatic capillary and the adjoining connective tissue area. Am J Anat. 1966; 118:785-809.
13. Roitt I, Brostoff J, Male D. Immunology. Mosby International. London. 1998.
14. Skobe M, Detmar M. Structure, function, and molecular control of the skin lymphatic system. J Invest Dermatol. 2000;5: 14-19.
15. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangio-genesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc Res Tech. 2001;55:122-145.
16. Hosking B, Makinen T. Lymphatic vasculature: a molecular perspective. BioEssay. 2007;29:1192-1202.
17. Wigle JT, Harvey N, Detmar M. et al. An essential role for Prox 1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002;21:1505-1513.
18. Veikkola T, Jussila L, Makinen T. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20:1223-1231.
19. Nerlich AG, Schleicher E. Identification of lymph and blood capillaries by immunohistochemical staining for various basement membrane components. Histochemistry. 1991;96: 449-453.
20. Lymboussaki A, Partanen TA, Olofsson B. et al. Expression of the vascular endothelial growth factor C receptor VEGFR - in lymphatic endothelium of skin and in vascular tumors. Am J Pathol. 1998;153:395-403.
21. Jussila L, Valtola R, Partanen T. et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against vascular endothelial growth factor receptor-3. Cancer Res. 1998;58:1599-1604.
22. Sleeman J.P, Krishnan J, Kirkin V. et al. Markers for the lymphatic endothelium: In search of the holy grail? Microsc Res Tech. 2001;55:61-69.
23. Jackson DG. New molecular markers for the study of tumour lymhangiogenesis. Anticancer Res. 2001;21:4279-4283.
24. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol. 2001; 22:317-321.
25. Prevo R, Banerji S, Ferguson D, Clasper S, Jackson D. Mouse LYVE-1 is an endocytic receptor for hyaluronate in lymphatic endothelium. J Biol Chem. 2001;276:19420-19430.
26. Carreira CM, Nasser SM, di Tomaso E. et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoid and down-regulation in human liver cancer and cirrhosis. Cancer Res. 2001;61:8079-8084.
27. Wróbel T, Dziȩgiel P, Mazur G. et al. LYVE-1 expression on high endothelial venules ( HEVs) of lymph nodes. Lymphology. 2005;38:107-110.
28. Koukourakis MI, Giatromanolaki A, Sivridis E. et al. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol. 2005; 58:202-206.
29. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today. 1995;16: 449-457.
30. Duijvestijn AM, Rep M, Hendriks HR. et al. Functional capacities of high endothelial venules appear not to be controlled by recirculating lymphocytes. Immunobiology. 1990; 180:295-307.
31. Faveeuw C, Preece G, Ager A. Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. Blood. 2001;98:688-695.
32. Rodriguez-Niedenfuhr M, Papoutsi M, Crist B. et al. Prox1 is a marker of ectodermal placodes, endodermal compartments, lymphatic endothelium and lymphangioblasts. Anat Embryol (Berl). 2001;204:399-406
33. Yuan L, Moyon D, Pardanaud L. et al. Abnormal lymphatic vessel development in neutropilin 2 mutant mice. Development. 2002;129;4797-806.
34. Breiteneder-Geleff S, Soleiman A, Kowalski H. et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154; 385-394.
35. Schacht V, Ramirez MI, Hong YK. et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003;22:3546-3556.
36. Scavelli C, Weber E, Agliano M. et al. Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat. 2004;204:433-449.
37. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin- binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858.
38. Leung DW, Cachianes G, Kuang WJ.et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
39. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol. 2000;11:617-624.
40. Gruchlik A, Chodurek E, Domal- Kwiatkowska D. et al. VEGF-A - the target of anti-angiogenic tumour therapy (in Polish). Post Biol Kom. 2007;3:557-580.
41. Nörje CJ, Mooney DJ, Polverini PJ. Vascular Endothelial Growth Factor (VEGF) - mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 1999;154:375-384.
42. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2000;19:6122-6129.
43. Olofsson K, Pajusola A, Kaipanen G. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 1996;93:2576-2581
44. Silvestre JS, Tamarat R, Ebrahimian TG. et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res. 2003;93:114-123.
45. Sun Y, Jin K, Childs JT. et al. Increased severity of cerebral ischaemic injury in vascular endothelial growth factor-B (VegfB)-deficient mice. J Cereb Blood Flow Metab. 2004; 24:1146-1152.
46. Sun Y, Jin K, Childs JT. et al. Vascular endothelial growth factor-B(VEGFB) stimulates neurogenesis: Evidence from knockout mice and growth factor administration. Develop Biol. 2006;289:329-335.
47. Karkkainen MJ, Haiko P, Sainio K. et al. Vascular endothelial growth factor C is required for sprouting of first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5:74-80.
48. Barańska P, Jerczyńska H, Pawłowska Z. Vascular endothelium growth factor: structure and functions (in Polish). Post Biochem. 2005;51:2-21.
49. Ishikawa M. Kitayama J, Kazama S. et al. Expression of vascular endothelial growth factor C and D (VEGF-C and VEGF-D) is an important riskfactor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn J Clin Oncol. 2003;33:21-27.
50. Yonemura Y, Endo Y, Fujita H. et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res. 1999;5:1823-1829.
51. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä- Herttuala S, Jäättelä M. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786-1790.
52. Baldwin ME, Catimel B, Nice EC. et al. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J Biol Chem. 2001;276:19166-19171.
53. Karkkainen M, Alitalo K. Lymphatic endothelial regulation, lymphoedema and lymph node metastasis. Semin Cell Dev Biol. 2002;13:9-18.
54. Kopfstein L, Veikkola T, Djonov VG. et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol. 2007;170:1348-1361.
55. Scagliarini A, Pozzo F, Gallina L. et al. In vitro activity of VEGF-E produced by orf virus strains isolated from classical and severe persistent contagious ecthyma. Vet Microbiol. 2006;114:142-147.
56. Zielonka TM. Angiogenesis. Part II. Factors modulating the process of new blood vessel development (in Polish). Alergia Astma Immunologia. 2004;9:25-31.
57. Kaipainen A, Korhonen J, Mustonen T. et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U.S.A. 1995;92:3566-3570.
58. Achen MG, Stacker SA. Tumor lymphangiogenesis and metastasic spread-new players begin to emerge. Int J Cancer. 2006;119:1755-1760.
59. Waś H. Characteristics of antigens and endothelial growth factors in lymph vessels (in Polish). Postep Biochem. 2005;2:209-214.
60. Waś H. Lymphangiogenesis: the younger sister of angiogenesis? How Achilles tendon was detected in tumours (in Polish). Wszechświat. 2005;106:7-9.
61. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta. 1654. 2004;3-12.
62. Skobe M, Hawighorst T, Jackson DG. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 2001;7:192-198.
63. Rubbia-Brandt L, Terris B, Giostra E. et al. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res. 2004;10:6919-6928.
64. Wong SY, Haack H, Crowley D. et al. Tumor-secreted vascular endothelial growth factor-C is necessary fo prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005;65:9789-9798.
65. Da MX, Wu Z, Tian HW. Tumor lymhangiogenesis and Lymphangiogenic Growth Factors. Arch Med Res. 2008;39:365-372.
66. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol. 2007;170:774-786.
67. Sundar SS, Ganesan TS. Role of Lymphangiogenesis in Cancer. J Clin Oncology. 2007;27:4298-4307.
68. He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65:4739-4746.
69. Mäkinen T, Jussila L, Veikkola T. et al. Inhibition of lymphangiogenesis with resulting lymphoedema in transgenic mice expressing soluble VEGF receptor-3. Nature Medicine. 2001;7:199-205.
70. Shields JD, Borsetti M, Rigby H. et al Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer. 2004;90:693-700.
71. Su JL, Yang PC, Shih JY. et al. The VEGF-C/VEGFR-3 axis promotes invasion and metastasis of cancer cells. Cancer Cell. 2006;9:209-223.
72. Kyzas PA, Geleff S, Batistatou A. et al. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol. 2005;206:170-177.
73. Chen CN, Sung CT, Lin MT. et al. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg. 2001;233:183-188.
74. Su JL, Shih JY, Yen ML. et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-Dependent Vascular Endothelial Growth Factor-C up-regulation: A novel mechanism of lymphangiogenesis in lung adanocarcinoma. Cancer Res. 2004; 64:554-564.
75. Da MX, Wu XT, Wang J. et al. Expression of cyclooxygenase -2 and vascular endothelial growth factor-c correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39:92-99.
76. Chang LK, Garcia-Cardena G, Farnebo F. et al. Dose dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA. 2004;101:11658- 11663.
77. Tammela T, Saaristo A, Lohela M. et al. Angiopoetin-1 promotes lymphatic sprouting and hyperplasia. Blood. 2005;105: 4649-4656.
78. Bjorndahl M, Cao R, Nissen LJ. et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA. 2005;102:15593-15598.
79. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human diseases. Nature. 2005;438:946-953.
80. Cao R, Bjorndahl MA, Religa P. et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004;6:333-345.
81. Cao R, Bjorndahl MA, Gallego MI. et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood. 2006;107:3531-3536.
82. Nakamura Y, Yosuoka H, Zuo H. et al. Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis. J Clin Endocronol Metab. 2006;91:1582-1585.
83. Sihoe AD, Yim AP. Lung cancer staging. J Surg Res. 2004;117:92-106.
84. Stacker SA, Caesar C, Baldwin ME. et al. VEGF-D promotes the metastatic spread of tumor cells via the lymhatics. Nature Med. 2001;7:186-191.
85. Kajita T., Ohta Y., Kimura K. et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 2001;85,255-260.
86. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, Cand D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 2000;6:2431-2439.
87. Ogawa E, Takenaka K, Yanagihara K. et al. Clinical significance of VEGF-C status in tumor cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer 2004;91:498-503.
88. Kadota K, Huang C, Liu D. i wsp. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057-1067.
89. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol 2008;3:124-127.
90. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD 2171 in lung cancer. Clin Cancer Res. 2007;13: 4617-4622.
91. Heckman CA, Holopainen T, Wirzenius M. et al. The tyrosine kinase inhibitor Cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008;68:4754-4762.
92. He Y, Kozaki K, Karpanen T. et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by bloking vascular endothelial growth factor receptor 3 signalin. J Natl Cancer Inst. 2002;94:819-825.
93. Krishnan J, Kirkin V, Steffen A. et al. Differential in vivo and in vitro expression of vascular endothelial growth factor VEGF-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 2003;63:713-722.
94. Motzer RJ, Michaelson MD, Redman BG. et al. Activity of SU 11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor in Patients with Metastatic Renal Cell Carcinoma. J Clin Oncol. 2006;24:16-24.
95. Kirkin V, Thiele W, Baumann P. et al. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer. 2004;112: 986-993.
96. Lin J, Lalani AS, Harding TC. et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005;65:6901-6909.
97. Achen MG, Roufail S, Domagala T. et al. Monoclonal antibodies to vascular endothelial growth factor - D block interactions with both VEGF receptor-2 and VEGF receptor-3. Eur J Biochem. 2000;267:2505-2515.
98. Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21;60-65.